Ajer Jeffrey Robert 4

What Happened

• Jeffrey Robert Ajer, a director of Viridian Therapeutics (VRDN), was granted a derivative award on 2026-07-01 covering 32,341 shares. The Form 4 reports an acquisition at $0.00 (derivative), meaning this is an option/award rather than a cash purchase; reported value on grant is $0.00 in the filing. This is a compensation/award transaction, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01 (reported on Form 4 filed 2026-07-02).
• Amount: 32,341 shares; reported price: $0.00 (derivative award/option).
• Vesting: The option vests in full upon the earlier of (i) July 1, 2027 or (ii) the issuer's 2027 annual meeting of stockholders, subject to Ajer’s continued board service (Footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Filed the day after the transaction date (appears timely); no indication of a late filing in this record.
• No immediate exercise or sale reported—this is a grant that vests in the future.

Context

• This is a routine equity award to a board member as compensation and does not by itself indicate buying or selling sentiment. For retail investors, the important follow-ups are (a) when/if the option vests and is exercised, and (b) any subsequent sales by the insider. Options vesting tied to continued service are common for directors and are intended as long-term alignment with shareholders.